GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) are contraindicated during breastfeeding per UK Summary of Product Characteristics No weight loss injection currently has regulatory approval for use whilst breastfeeding in the UK Transfer into breast milk and effects on nursing infants remain unknown due to absence of human studies Appetite suppression from these medications may compromise maternal nutrition needed for adequate milk production Safe alternatives include gradual dietary modification, regular physical activity, and NHS weight management programmes Women should defer weight loss medications until breastfeeding is completed and seek GP advice for postpartum weight concerns Table of Contents Weight Loss Injections and Breastfeeding: Key Safety Considerations Types of Weight Loss Injections and Their Use During Lactation Potential Risks to Breastfed Infants Alternative Approaches to Postpartum Weight Management When to Seek Medical Advice About Weight Loss While Breastfeeding Frequently Asked Questions Weight Loss Injections and Breastfeeding: Key Safety Considerations Weight loss injections, particularly GLP-1 receptor agonists such as semaglutide (Wegovy) and liraglutide (Saxenda), have become increasingly popular for weight management
[10] [12] High doses of ascorbic acid can increase the absorption of iron from the gastrointestinal tract and may potentiate the effects of oral iron supplementation or exacerbate iron overload in susceptible individuals
By reducing inflammation, B-complex vitamins could potentially alleviate soreness and promote faster recovery
Those with an intake of the drugs for a longer period (one to two years) were at higher risk of kidney failure and other kidney-related problems
Administration: Intramuscular (IM) injections are commonly used
Has my b levels on point More energy Love this stuff
